Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by consultant99on Mar 11, 2024 2:47pm
234 Views
Post# 35926919

RE:TLD 1433 Patent expiry July, 2034

RE:TLD 1433 Patent expiry July, 2034

Always been a concern that getting FDA approval would take too long and reduce the value of an acquisition due to the limited patent time remaining. 

Part of the process is the laser device. Will TLT or its successor company owns the laser? If so the generic drug manufacturer would need their own approved laser and that might be a deterrent. 

 I would look at the newest PDT drug that Theralase will use for brain and lung cancer, run clinical trials and get it approved for bladder cancer. I would expect further improvement in the results achieved. 

If successful it would reset the patent protection. By the time TLT or it's successor company would need to run the trials money should not be an issue. 

<< Previous
Bullboard Posts
Next >>